Imprimis Pharmaceuticals (IMMY) Trading Down 5.5%

Share on StockTwits

Shares of Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) traded down 5.5% during mid-day trading on Monday . The company traded as low as $4.90 and last traded at $5.00. 518,922 shares were traded during mid-day trading, an increase of 94% from the average session volume of 267,697 shares. The stock had previously closed at $5.29.

The company has a current ratio of 1.13, a quick ratio of 0.88 and a debt-to-equity ratio of 2.84.

Imprimis Pharmaceuticals (NASDAQ:IMMY) last announced its earnings results on Tuesday, November 13th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). The firm had revenue of $10.74 million during the quarter. Imprimis Pharmaceuticals had a negative net margin of 16.81% and a negative return on equity of 231.16%.

In related news, Director Robert J. Kammer sold 10,000 shares of the company’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $3.00, for a total value of $30,000.00. Following the completion of the sale, the director now directly owns 919,827 shares of the company’s stock, valued at approximately $2,759,481. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders sold 30,000 shares of company stock valued at $102,100. Insiders own 13.78% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in IMMY. Northern Trust Corp boosted its position in shares of Imprimis Pharmaceuticals by 145.8% in the 1st quarter. Northern Trust Corp now owns 67,013 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 39,750 shares during the period. Birchview Capital LP acquired a new stake in Imprimis Pharmaceuticals during the 2nd quarter worth approximately $396,000. Granite Investment Partners LLC lifted its position in Imprimis Pharmaceuticals by 153.8% during the 2nd quarter. Granite Investment Partners LLC now owns 170,962 shares of the specialty pharmaceutical company’s stock worth $376,000 after acquiring an additional 103,607 shares during the period. Ardsley Advisory Partners lifted its position in Imprimis Pharmaceuticals by 42.9% during the 2nd quarter. Ardsley Advisory Partners now owns 100,000 shares of the specialty pharmaceutical company’s stock worth $220,000 after acquiring an additional 30,000 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Imprimis Pharmaceuticals by 104.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 117,990 shares of the specialty pharmaceutical company’s stock worth $328,000 after acquiring an additional 60,248 shares during the period. 10.03% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was published by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://baseballnewssource.com/2018/11/20/imprimis-pharmaceuticals-immy-trading-down-5-5/3014706.html.

About Imprimis Pharmaceuticals (NASDAQ:IMMY)

Imprimis Pharmaceuticals, Inc, an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications.

Recommended Story: Compound Interest

Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.